CD46 and Schnyder corneal dystrophy: In vitro transduction studies with HSC-enriched cell fractions from CD46/Townes (BM Lin− cells) and SCD patients (CD34+ cells) resulted in target site editing (A7 > G) at a rate of ∼21% and 35%, respectively.